A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Ian W. Flinn Farrukh T Awan Jennifer A Woyach Gerard Lozanski John C. Byrd |
| Publication date | October 9, 2014 |
| Language | English |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |